Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Lexaria Receives USD$2.6 Million Tax Rebate Payment
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
Lexaria Enters a Material Transfer Agreement With PegBio
Lexaria Announces Effective Date for Reverse Stock Split
Lexaria Updates Business Development
Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.